SensoDetect (SDET) Q1 2025 earnings summary

Executive summary

• Strengthened international presence via a joint venture in China with Beijing Haierxi Medical Technology Co., securing guaranteed revenue and future growth potential.

• Completed a directed share issue after a successful warrant exercise, raising approximately 20 MSEK before costs.

• Enhanced medical advisory team and advanced the autism study "Early, Objective Detection of Autism."

Financial highlights

• Net sales for Q1 2025 were 120 KSEK, up from 6 KSEK in Q1 2024.

• Result after financial items improved to -1,948 KSEK from -2,312 KSEK year-over-year.

• Earnings per share were approximately -0.005 SEK, compared to -0.01 SEK in Q1 2024.

• Cash flow from operating activities was 3,098 KSEK, down from 11,899 KSEK in Q1 2024.

• Cash and cash equivalents at period end were 12,055 KSEK, up from 6,829 KSEK a year earlier.

Outlook and guidance

• JV in China guarantees at least 7.8 MSEK in revenue over two years, with accelerated revenue growth expected from H2 2026.

• Management targets positive cash flow within 2025 and aims for accelerated global expansion and profitability.